INmune Bio
INMB
73 hedge funds and large institutions have $9.64M invested in INmune Bio in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 22 closing their positions.
20% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $991K
6.96% less ownership
Funds ownership: 24.48% → 17.51% (-7%)
8% less funds holding
Funds holding: 79 → 73 (-6)
13% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 23
24% less capital invested
Capital invested by funds: $12.7M → $9.64M (-$3.09M)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$314K |
| 2 |
WIM
Westside Investment Management
Santa Monica,
California
|
+$188K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$182K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$141K |
| 5 |
Jane Street
New York
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$672K |
| 2 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$412K |
| 3 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$311K |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$211K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$176K |
INMB Hedge Fund Activity: Q3 2025 in Review
73 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q3 2025, worth a combined $9.64M — down 24% from $12.7M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of INMB and 16 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 20 added.
The largest buyer was Susquehanna International Group, adding an estimated $314K. The largest seller was UBS Group, cutting an estimated $672K.
- 73 institutional investors held INmune Bio (INMB) as of Q3 2025, down from 79 in Q2 2025.
- Funds reported $9.64M of INmune Bio stock for Q3 2025, down 24% quarter-over-quarter.
- 16 funds opened new INmune Bio positions in Q3 2025 and 22 closed out, a net change of -6 holders.
- The largest INmune Bio buyer in Q3 2025 was Susquehanna International Group, an estimated $314K added.
- The largest INmune Bio seller in Q3 2025 was UBS Group, an estimated $672K sold.
Based on aggregated 13F filings for Q3 2025.